Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$30.06 - $41.49 $3.28 Million - $4.53 Million
109,206 Added 24.98%
546,318 $17 Million
Q2 2024

Jul 29, 2024

SELL
$33.78 - $63.75 $2.71 Million - $5.11 Million
-80,092 Reduced 15.49%
437,112 $14.8 Million
Q1 2024

Apr 29, 2024

BUY
$60.14 - $75.36 $2.04 Million - $2.55 Million
33,868 Added 7.01%
517,204 $33.6 Million
Q4 2023

Feb 07, 2024

SELL
$42.85 - $69.5 $109,267 - $177,225
-2,550 Reduced 0.52%
483,336 $33 Million
Q3 2023

Nov 02, 2023

BUY
$49.5 - $66.6 $105,385 - $141,791
2,129 Added 0.44%
485,886 $25.2 Million
Q2 2023

Aug 07, 2023

BUY
$48.54 - $61.64 $1.45 Million - $1.85 Million
29,953 Added 6.6%
483,757 $29 Million
Q1 2023

May 09, 2023

SELL
$46.12 - $65.71 $2.22 Million - $3.17 Million
-48,179 Reduced 9.6%
453,804 $22.4 Million
Q4 2022

Feb 09, 2023

SELL
$45.51 - $65.08 $1.1 Million - $1.58 Million
-24,269 Reduced 4.61%
501,983 $28.6 Million
Q3 2022

Nov 09, 2022

BUY
$37.34 - $57.44 $8.45 Million - $13 Million
226,302 Added 75.45%
526,252 $24.7 Million
Q2 2022

Aug 10, 2022

BUY
$25.46 - $37.72 $1.64 Million - $2.43 Million
64,405 Added 27.34%
299,950 $11.2 Million
Q1 2022

May 09, 2022

BUY
$18.94 - $34.29 $20,947 - $37,924
1,106 Added 0.47%
235,545 $7.04 Million
Q4 2021

Feb 09, 2022

BUY
$27.58 - $40.0 $1.37 Million - $1.98 Million
49,514 Added 26.78%
234,439 $8.03 Million
Q3 2021

Nov 09, 2021

BUY
$27.98 - $40.0 $218,803 - $312,800
7,820 Added 4.42%
184,925 $6.86 Million
Q2 2021

Aug 10, 2021

BUY
$32.22 - $41.5 $1.72 Million - $2.22 Million
53,533 Added 43.32%
177,105 $6.92 Million
Q1 2021

May 24, 2021

BUY
$36.3 - $56.34 $4.49 Million - $6.96 Million
123,572 New
123,572 $5.26 Million

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.24B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.